Saltar al contenido
MilliporeSigma

Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells.

Free radical biology & medicine (2011-08-31)
Emanuela Pupo, Alessandra Fiorio Pla, Daniele Avanzato, Francesco Moccia, José-Everardo Avelino Cruz, Franco Tanzi, Annalisa Merlino, Daniele Mancardi, Luca Munaron
RESUMEN

Hydrogen sulfide (H(2)S) is a gasotransmitter that plays several roles in various tissues, including the cardiovascular system. Because it has been recently proposed to act as a mediator of angiogenesis progression, here we investigate the effects of H(2)S in a well-established model of tumor angiogenesis: endothelial cells obtained from human breast carcinoma (B-TECs). Ca(2+) imaging and patch-clamp experiments reveal that acute perfusion with NaHS, a widely employed H(2)S donor, activates cytosolic calcium (Ca(c)) increase, as well as potassium and nonselective cationic currents, in B-TECs. Stimulation with NaHS in the same concentration range (1 nM-200 μM) evoked Ca(c) signals also in "normal" human microvascular endothelial cells (HMVECs), but the amplitude was significantly lower. Moreover, although NaHS failed to promote either migration or proliferation on HMVECs, B-TEC migration was enhanced at low-micromolar NaHS concentrations (1-10 μM). Remarkably H(2)S mediates tumor proangiogenic signaling triggered by vascular endothelial growth factor (VEGF). B-TECs pretreated with dl-propargylglycine (5mM, 30 min), an inhibitor of the H(2)S-producing enzyme cystathionine γ-lyase, showed drastically reduced migration and Ca(c) signals induced by VEGF (20 ng/ml). We conclude that H(2)S plays a role in proangiogenic signaling of tumor-derived but not normal human ECs. Furthermore the ability of this gasotransmitter to interfere with B-TEC responsiveness to VEGF suggests that it could be an interesting target for antiangiogenic strategies in tumor treatment.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
DL-Propargylglycine, cystathionine γ-lyase inhibitor
Sigma-Aldrich
L-C-Propargylglycine, ≥99.0% (TLC)